Relación entre los niveles plasmáticos de triglicéridos y los polimorfismos -133T>C y 56C>G del gen codificante para la ApoA5

  1. Ismael San Mauro Martín 1
  2. Ana María Ruiz León 2
  3. Elena Garicano Vilar 2
  4. Javier Andrés Blumenfeld Olivares 3
  5. Eva Pérez Arruche 3
  6. Esperanza Arce Delgado 3
  7. María José Ciudad Cabañas 1
  8. Luis Collado Yurrita 1
  1. 1 Universidad Complutense de Madrid
    info

    Universidad Complutense de Madrid

    Madrid, España

    ROR 02p0gd045

  2. 2 Grupo CINUSA
  3. 3 Hospital El Escorial de Madrid
    info

    Hospital El Escorial de Madrid

    San Lorenzo del Escorial, España

Mostrar afiliacións +
Revista:
Journal of Negative and No Positive Results: JONNPR

ISSN: 2529-850X

Ano de publicación: 2016

Volume: 1

Número: 1

Páxinas: 31-35

Tipo: Artigo

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Outras publicacións en: Journal of Negative and No Positive Results: JONNPR

Resumo

Aim. The aim was to evaluate the association between polymorphisms -113C>T (rs662799) and 56C>G (rs3135506) and plasmatic triglycerides levels in adults. Methods. A randomized clinical trial of 44 subjects from two hospital centers from Madrid (Spain). Anthropometric survey, blood test, genetic analysis and an Ad hoc survey (lifestyle habits: nutrition, physical activity, sleep) were conducted. Results. No statistically significant differences were observed between polymorphism 113G>T or 56C>G and plasmatic triglycerides concentrations (p>0.05). However, statistically significant differences were found between gene variant 56C>G and total cholesterol levels and low-density lipoproteins (p=0.015 and p=0.036, respectively). Conclusion. This trial brings to light no association between plasmatic triglycerides levels and polymorphic variants 56C>G and - 1131T>C of Apo5 coding gene.

Referencias bibliográficas

  • Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al; European
  • Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition,
  • diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655-66.
  • WHO.int. Cardiovascular diseases [página Web]. [Fecha de actualización: 2015 ene; 2016 may 18]. Disponible en:
  • http://www.who.int/mediacentre/factsheets/fs317/en/
  • Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626-35.
  • Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. An apolipoprotein influencing
  • triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169-73.
  • San Mauro-Martín I, de la Calle-de la Rosa L, Sanz-Rojo S, Garicano-Vilar E, Ciudad-Cabañas MJ, Collado-Yurita L.
  • Enfoque genómico en la enfermedad cardiovascular. Nutr HosP. 2016;33(1)148-55.
  • Li S, Hu B, Wang Y, Wu D, Jin L, Wang X. Influences of APOA5 variants on plasma triglyceride levels in Uyghur
  • population. PLoS One. 2014;9(10):e110258.
  • Portao J, Bescós R, Irurtia A, Cacciatori E, Vallejo L. Valoración de la grasa corporal en jóvenes físicamente activos:
  • antropometría vs bioimpedancia. Nutr Hosp. 2009;24:529-34.
  • Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem.
  • ;20(4):470-5.
  • Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al. Direct measurement of high-density lipoprotein
  • cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem.
  • ;41(5):717-23.
  • Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular
  • disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of
  • Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by
  • representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-701.
  • Guardiola M, Cofán M, de Castro-Oros I, Cenarro A, Plana N, Talmud PJ, et al. APOA5 variants predispose
  • hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis. 2015;240(1):98-
  • Li S, Hu B, Wang Y, Wu D, Jin L, Wang X. Influences of APOA5 variants on plasma triglyceride levels in Uyghur
  • population. PLoS One. 2014;9(10):e110258.
  • Fallah MS, Sedaghatikhayat B, Guity K, Akbari F, Azizi F, Daneshpour MS. The relation between metabolic syndrome
  • risk factors and genetic variations of apolipoprotein V in relation with Serum triglyceride and HDL-C level. Arch Iran
  • Med. 2016;19(1):46-50.
  • Halalkhor S, Jalali F, Tilaki KH, Shojaei S. Association of two common polymorphisms of apolipoprotein A5 gene with
  • metabolic syndrome indicators in a North Iranian population, a cross-sectional study. J Diabetes Metab Disord.
  • ;13:48.
Fonte de datos: Dialnet